Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Rood, Zhenjiang, 212001, China,
Clin Transl Oncol. 2013 Nov;15(11):882-8. doi: 10.1007/s12094-013-1017-1. Epub 2013 Feb 12.
The long-term survival of patients with completely resected stage I non-small cell lung cancer (NSCLC) is not optimal because of undetected lymph node micrometastasis at the time of surgery. The aim of this study is to evaluate the role of survivin and livin mRNA expression in histopathologically negative lymph nodes of stage I NSCLC patients as markers of micrometastasis.
Clinical data and tissue samples of primary tumor and lymph nodes were collected from 44 patients with stage I NSCLC. Reverse-transcriptase-PCR (RT-PCR) was used to detect survivin and livin mRNA expression in these tumor and lymph node samples.
Survivin mRNA was detected in all tumors, and livin mRNA was detectable in 39 of the 44 primary tumors. The cut-off values of survivin and livin mRNA levels for diagnosing micrometastasis in lymph nodes were set up according to the expression of survivin and livin mRNA in control lymph nodes. Fifteen (34.1 %) of 44 stage I NSCCL patients had micrometastasis in lymph nodes by survivin and/or livin mRNA positive expression. Survival analysis showed higher rate of cancer recurrences and tumor-related death in patients with lymph node micrometastasis (P < 0.001 and P = 0.001, respectively). Tumor-free survival and overall survival were significantly worse in patients with lymph node micrometastasis compared with those without such micrometastasis (P = 0.007 and P = 0.01, respectively).
RT-RCR assay for survivin and livin mRNA can be considered as useful diagnostic tool for the detection of lymph node micrometastasis for stage I NSCLC patients.
由于在手术时无法检测到淋巴结的微转移,完全切除的 I 期非小细胞肺癌(NSCLC)患者的长期生存情况并不理想。本研究旨在评估生存素和 livin mRNA 在 I 期 NSCLC 患者的病理阴性淋巴结中的表达作为微转移的标志物的作用。
收集 44 例 I 期 NSCLC 患者的临床资料和原发肿瘤及淋巴结组织样本。采用逆转录-聚合酶链反应(RT-PCR)检测这些肿瘤和淋巴结样本中的生存素和 livin mRNA 表达。
所有肿瘤均检测到生存素 mRNA,44 例原发肿瘤中有 39 例可检测到 livin mRNA。根据对照淋巴结中生存素和 livin mRNA 的表达,确定了用于诊断淋巴结微转移的生存素和 livin mRNA 水平的临界值。44 例 I 期 NSCLC 患者中有 15 例(34.1%)通过生存素和/或 livin mRNA 阳性表达存在淋巴结微转移。生存分析显示,淋巴结微转移患者的癌症复发率和肿瘤相关死亡率较高(P<0.001 和 P=0.001)。与无淋巴结微转移的患者相比,淋巴结微转移患者的无病生存率和总生存率显著降低(P=0.007 和 P=0.01)。
RT-RCR 法检测生存素和 livin mRNA 可作为检测 I 期 NSCLC 患者淋巴结微转移的有用诊断工具。